ViiV Healthcare Presents Potential Long-Acting HIV Therapies
March 17th 2025Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
Watch
The M&M Study: Age-Related T Cell Response in People with HIV on ART in MVA.HIVconsvX Vaccine Trial
March 10th 2025Nilu Goonetilleke, LLBHons, BScHons, presents findings from the phase 1 study, showing a 50% reduction in T cell response with age, while 85% of participants demonstrated strong immune responses.
Watch